Immutep Stock Plummets 82.6% on Failed Clinical Trial; Class Action Probe Launched
Immutep's $IMMP stock crashed 82.6% after discontinuing Phase III trial for lead drug candidate. Rosen Law Firm investigating potential securities violations and class action claims.
IMMPsecurities fraudclass action lawsuit